International Journal of Multiphysics
Volume 18, No. 3, 2024
ISSN: 1750-9548

Comparative Effectiveness of Tamsulosin Plus Tadalafil and Tamsulosin Alone after Shock Wave Lithotripsy for Renal Pelvic Calculi

Karim Ibrahim Abdelfattah Mohamed Elsemary*, Hussein Mohamed Kamel, Ahmed Ragab Ali, Diab ElSayed Mohamed

Department of Urology, Faculty of Medicine, Zagazig University

***Corresponding author:** Karim Ibrahim Abdelfattah Mohamed Elsemary

Abstract:

Urolithiasis is a prevalent urological condition that is defined by the formation of crystal aggregates that have the potential to traverse the urinary tract. The term urolithiasis is derived from the Greek words uro (urinary) and lithos (stone). The earliest reference to renal stones is found in the ancient Mesopotamian medical texts, which date back to 3200–1200 BC. Urolithiasis is a condition that is becoming more prevalent worldwide and affects 1–20% of the global population. All age groups are experiencing a considerable health burden as a result, which emphasizes the need for efficient public health measures to combat this illness. The ureters account for about 22% of urolithiasis cases. Urolithiasis develops when solutes crystallise out of urine to form calculi. Shock wave lithotripsy (SWL) is the primary treatment option for the majority of patients with urolithiasis. It has a reported clearance rate of 66%–99% for kidney stones smaller than 20 mm. The SWL procedure is characterized by high patient compliance and can be performed in an ambulatory setting, with or without anesthesia. Additionally, it has a low morbidity. Various factors, including the location and composition of the stone, the anatomy of the pelvicalyceal system, the lithotripter used, body mass index, and ureteral condition (including spasm and edema), influence the success rate of SWL. In spite of this, renal distress and substantial rates of retreatment persist after the procedure. Medical expulsive therapy (MET) has been instituted by numerous institutions as an adjunctive treatment in order to enhance the outcomes of SWL and achieve higher rates of stone-freeness. Calcium channel blockers and alpha-1 adrenergic receptor antagonists have emerged as the primary established treatments for MET in recent years. Tamsulosin and nifedipine both affect the ureteral muscle, which in turn aids in the relaxation and dilation of the ureter, thereby facilitating the elimination of stone fragments. We aimed to assess the effect of tamsulosin as an adjunct medical expulsion therapy after SWL for renal stones.

Keywords: Tamsulosin, Tadalafil, Tamsulosin, Expulsive Therapy, Post Renal Pelvic Stone, Shock Wave Lithotripsy.

Introduction

The urinary tract stones incidence is increasing, and it affects 1–15% of the general population. The majority of these stones will spontaneously dissolve. The passage of a stone is dependent upon two primary factors: the stone size and its location within the urinary system. These criteria determine the passing rate of stones; for stones smaller than 5 mm, the passage rate is between 40% and 98%, and for stones larger than 5 mm, it is between 55% and 50%. α-adrenergic receptors in the urinary smooth muscles have been shown to facilitate contraction, resulting in renal colic and ureteric contractions when stones are present. Spasmodic contractions of these smooth muscles are the result of stones, which prevent expulsion by causing disorganised contractions and ultimately stasis. Additionally, the stone's reactive inflammation will induce mucosal oedema, which may result in obstruction by increasing stasis (1).

Since 1984, extracorporeal shock wave lithotripsy (ESWL) has been regarded as renal and ureteric stones fundamental treatment. It is presently considered the preferred treatment for small and medium-sized stones and is one of the most highly recommended options in most guidelines. It employs external equipment that generates intense pressure waves to pulverise hard concretions, such as urinary stones, into passable, small fragments. This method is distinguished by its non-invasive nature, which enables shock waves to pass through body tissues, concentrates energy on the stone, and reduces patient distress, thereby facilitating a quicker recovery (2).

The lower ureter contains a higher density of α-adrenergic receptors than the mid or upper ureter. Basal smooth muscle tone, amplitude, and peristaltic frequency are inhibited by the use of an α-blocker, while tonic propulsive contractions are maintained. This causes fluid movement to rise and intra-ureteric pressure to decrease. Additionally, calcium decreases smooth muscle contraction and relaxation, and calcium channel blockers (CCBs) can decrease intra-ureteric pressure and improve fluid transfer similarly to α-blocker (3). After SWL for renal stones, we wanted to assess the effectiveness of tamsulosin as a supplemental medical expulsion treatment.

Urolithiasis

A complicated urological condition, urolithiasis is characterized by calculi that develop in the kidneys, urethra, and bladder. Urolithiasis has long been prevalent in humans, but it still presents significant health and medical challenges. Calculi of the calcium oxalate (CaOx) variety are the most prevalent in urolithiasis. Calculi can also be caused by drugs, uric acid, cystine, struvite, xanthine, ammonium acid urate, and dihydroxyadenine (4).

- **Epidemiology**

The incidence of urolithiasis varies geographically, with Western countries generally experiencing increase rates than those in the Eastern hemisphere. Asia has an incidence rate of approximately 1–5%, Europe has an incidence rate of 5–9%, and Canada has an incidence rate of 12%. The United States has an incidence rate of 13–15%. 20.1% is a particularly high incidence rate in Saudi Arabia. The condition is most common in individuals in their thirties and forties, with an increase prevalence in males than in females. Influencing factors include sex and age. Changes in diet and lifestyle are likely to be associated with the increasing prevalence of urolithiasis over time. Globally, the number of cases of urolithiasis, disability-adjusted life years, and mortality rates have all increased (5).

- **Pathophysiology of urolithiasis**

Urolithiasis is a multifaceted and intricate condition that is influenced by both genetic and environmental factors. The CaOx stones formation is distinct from that of other forms of stones, and the urinary stones development is influenced by a variety of mechanisms. Stone-forming metabolites build up in the digestive system due to either impaired renal acidification, decreased renal excretion, or excessive absorption. Randall plaques and mineral deposits are among the unique pathomechanisms implicated in the CaOx stones formation. To identify the most effective preventative and therapeutic strategies, more study is necessary as the pathophysiology and development of CaOx stones are still poorly understood. Recent research suggests that the initial phase of CaOx stone formation could be the development of interstitial apatite crystals (6).

- **Mechanism of stone formation**

When a person has low urine volume, low pH, or high urinary supersaturation—risk factors for stone development crystals may nucleate and aggregate into larger particles, which could result in the formation of a stone. Genetics, diet, lifestyle, and medical disorders including metabolic illnesses or urinary tract infections can all contribute to the development of stones. In addition to producing discomfort and other symptoms, a stone can spread by creating new crystals and moving about in the urinary tract. The size and chemical makeup of a stone may affect its ability to pass through the urinary tract. Smaller stones are more likely to go away on their own, while larger stones could need medical assistance to be removed (7).

- **Clinical presentation and evaluation**

The most prevalent manifestation of nephrolithiasis is haematuria accompanied by pain of varying intensity. It is paroxysmal, has a sudden start, and is characterized by waxing and waning. The obstruction site and the pain location are connected, and as the stone moves, the discomfort may change. The majority of patients experience gross or microscopic haematuria. Microhaematuria had a 95% sensitivity when tested on the first day of treatment in a retrospective investigation of subjects with acutely symptomatic nephrolithiasis. However, the sensitivity decreased to 65% when testing was conducted on the third and fourth days after the onset of pain (8).

Dysuria, urgency, vertigo, and vomiting are additional symptoms that may be present. In the majority of instances, stone passages offer nearly immediate alleviation. Some patients pass "gravel," which is frequently observed in conjunction with uric acid stones. Acute kidney injury from obstructive nephropathy and infection are among the complications of nephrolithiasis. Finding possible causes and targeted treatments requires a thorough medical history that emphasizes kidney stone risk factors. The history should include the following: the type of stone, the frequency and number of stone events, the laterality of the stones, the type and number of surgical procedures, the concurrent infections, the age at which the first stone occurrence happened, and the family history of stones (9).

Kidney stones may be a consequence of a recognized clinical problem or the first sign of an illness. One of the most common predisposing diseases is the metabolic syndrome. The likelihood of producing CaOx stones is increased in patients with malabsorption resulting from Crohn's disease, gastric bypass, cystic fibrosis, or celiac disease. Lithium use, multiple endocrine neoplasia in the family, and neck radiation all raise the risk of primary hyperparathyroidism. Stone disease may be more likely to occur in people with autoimmune diseases like Sjögren's syndrome as a result of distal renal tubular acidosis (RTA) (10).

Medication use, including over-the-counter medications and supplements, should also be included in the history. Drug-induced nephrolithiasis is exceedingly uncommon, accounting for only 1% to 2% of all renal calculi. The drug direct crystallization or its metabolites altering the supersaturation of normally occurring solutes are 2 main mechanisms by which drugs may promote stone formation. This phenomenon is observed with other carbonic anhydrase inhibitors and topiramate. Individuals are at calcium phosphate nephrolithiasis risk and topiramate due to the alkaline urine and hypocitraturia that result from metabolic acidosis. A urinalysis with microscopy, intact parathyroid hormone, serum phosphate, serum uric acid, and a complete metabolic profile should be routinely included in laboratory tests for the nephrolithiasis evaluation. Additionally, a urine culture should be obtained in patients who exhibit symptoms of a urinary tract infection. Metabolic acidosis and hypokalaemia are indicative of RTA, particularly when the urine pH is ≥ 6.5. Inadequate fluid consumption is indicated by a high urine specific gravity. Urine microscopy may reveal crystalluria, which can provide information regarding the subtype of the stone. disclose the crystals' appearance that may be discovered (11).

Non-contrast helical CT is the recommended imaging modality for kidney stone diagnosis because of its improved sensitivity and specificity, precision in size and location delineation, and capacity to identify almost any type of stone (apart from those brought on by protease inhibitors). Cost and radiation exposure are the primary drawbacks. The ultrasound sensitivity is low, despite its high specificity. In the acute setting, this modality is an effective screening test for obstruction and is also used to limit the radiation exposure of paediatric and pregnant patients. The plain abdominal X-ray imaging can be employed to evaluate stone growth, recurrence, or clearance in patients with documented radiopaque stones, thereby minimising radiation exposure (12).

Attempts should be made to collect stones for formal compositional analysis in all cases, either through the meticulous use of the urine strainer or during stone extraction procedures. A struvite, cystine, or uric acid stone-former case is identified by the presence of any quantity of these minerals in the stones. CaOx or calcium phosphate stone-formers are typically classified as cases in which the mineral content of calcium stones exceeds 50%. In cases of recurrent nephrolithiasis, the primary method of evaluation is a 24-hour urine collection, or two collections if possible. When the composition of the stone is unknown, as is the case in up to 50% of incident stone-formers, this may be the sole device available to guide therapy. Since people are prone to changing their habits during an acute episode, the collection should take place in an outpatient environment under stable settings while the patient is eating their usual diet [13].

Table 1 shows types of urolithiasis and treatment.

Table 1: Types of urolithiasis and treatment

Type of Stone	Prevalence	Etiology / Risk Factors	Treatment / Prevention
Calcium oxalate (CaOx)	~50% of all stones	Hypercalciuria; imbalance in urine chemistry (sodium, citrate, oxalate, uric acid, calcium, specific gravity)	Regulate urine chemistry via dietary and metabolic control [14]
Calcium phosphate	10–20%	Renal phosphate leakage; hyperphosphaturia	Prevent recurrence by managing phosphate levels; monitor urinary phosphate [15]
Uric acid	~10%	Hyperuricosuria; low urine pH; low urinary volume	Endoscopic/chemotherapeutic treatment; surgical options (percutaneous nephrolithotomy, extracorporeal shock wave lithotripsy); urine alkalinization [16]
Struvite (magnesium ammonium phosphate)	10–15%	UTIs with urease-producing bacteria (Proteus, Klebsiella); high urine pH	Treat/prevent UTIs with antibiotics; good hygiene; adequate fluid intake [17]
Cystine	Rare	Genetic disorder (cystinuria); high urinary cystine concentration	High fluid intake; low-sodium diet; reduced animal protein; medications (tiopronin, D-penicillamine); surgical intervention if needed [18]

Shock wave lithotripsy

Until shock wave lithotripsy (SWL) was introduced into clinical practice in the early 1980s, most urinary stones were removed through open surgery. Often challenging, this treatment had a significant risk of complications and necessitated a long period of recovery in the hospital. Because stone disease was recurrent, stone formers frequently had several very invasive surgeries done over time. The SWL safely removed urinary tract stones using high-intensity sonic pulses. Almost any stone can be removed with it without putting the kidney or urinary system at risk. The new technology was avidly promoted in early reports, and SWL was applicable in even the most complex cases, including stones in solitary kidneys, multiple stones, bilateral stones, and staghorn calculi. Nevertheless, urologists began to acknowledge the limitations of lithotripsy as their experience with the procedure increased. Some stone varieties, such as brushite, cysteine stones, and CaOx monohydrate, may be resistant to SWL [19].

The presence of residual fragments frequently required re-treatment, and fracture was not always complete among stones that could be easily broken. Furthermore, certain features of the renal anatomy, such as the acute infundibulopelvic angle, calyceal diverticula, and lower pole calyx, may make the removal of stone debris more challenging. Additionally, because of the ureter's extremely limited capacity to remove stone fragments, SWL treatment has to be limited to a stone burden of less than about 2.5 cm. The unexpected and even serious negative effects of SWL were also being described in publications. The possibility that shock waves could burst blood vessels and cause serious bleeding became clear. The intraparenchymal haemorrhage occurrence and massive renal haematomas necessitating transfusion or even nephrectomy was reported in case studies. Haematomas of the liver and pancreas, splenic rupture, and intra-abdominal bleeding were also reported as extrarenal injury [20].

Consequently, the issues were too significant to be ignored in the face of the innumerable successful cases. Basic studies were first conducted to characterize the acute renal damage caused by SWL in response. The lesion was focal but not limited to the size of the focal zone, according to research primarily employing the Dornier HM3 lithotripter in the pig model. Shock wave amplitude and quantity were influenced by dose-dependent lesion size. Particularly susceptible to shock wave damage was the renal papilla. The study found that bleeding might cause an inflammatory response that could lead to scarring and a permanent decrease in functional renal volume, tubular injury could happen but was usually the result of vessel rupture, and the lesion might affect a number of vessels. In spite of the short-term impairment of glomerular and tubular function, a thorough assessment of renal function demonstrated that the kidney swiftly demonstrated recovery [21].

One important finding was that the kidney could experience a vasoconstrictive response even after brief exposure to shock waves. Treatment plans that may greatly reduce tissue damage in SWL have been developed as a result of these observations. Therefore, studies on the acute response to treatment helped to highlight the possible harm caused by shock waves and the significance of technique optimization to enhance results. The potential for long-term impairment as a result of SWL is relatively unknown. The shock waves adverse effects have never been adequately investigated in animal models over an extended period. Clinical investigations provide the most comprehensive information regarding the chronic effects potential in SWL. While the findings are not entirely consistent, there is sufficient evidence to raise concerns regarding the potential for some patients, especially those who are older or have had several lithotripsies, to develop serious and long-lasting chronic conditions, such as diabetes mellitus and new-onset hypertension. Additionally, there may be a correlation between the stone disease complexity and severity, the multiple treatment sessions necessity, and injury to the renal papilla [22].

In general, lithotripsy provides significant advantages for the renal and ureteral stones treatment. Treatment for isolated, simple stones can be achieved using SWL, a noninvasive procedure that can be done as an outpatient. Due to the ureter's limited ability to release stone fragments, therapy is limited to a maximum stone load of approximately 2.5 cm. Incomplete stone breakdown may require additional surgery or retreatment to remove any leftover particles that are clinically significant. Some stones are difficult for shock waves to break. Furthermore, SWL has some disadvantages. The potential for significant acute renal and extrarenal damage from shock wave exposure is another drawback, with concerns that in certain cases, acute injury could progress to chronic damage [22].

- **Current status of SWL in the clinic**

It is commonly known that the clinical context serves as the foundation for SWL therapy methods. A number of variables, including the expertise and preferences of the particular urologist and the availability of facilities, affect the choice of treatment modality. The performance of lithotripsy is also influenced by similar factors. Lithotripsy is not administered uniformly across all institutions or locales. It is comprehensible that there are variations in protocol; however, local practice frequently diverges from what is considered "best practice." [23].

The manner in which shock waves are delivered can significantly influence the adverse effects and the outcomes occurrence. In summary, the shock wave dose should be minimised and the treatment should be administered at a sluggish rate, as indicated by well-substantiated evidence. The number of shock waves and the pulse amplitude in a single session determine how much kidney damage occurs, and performing several lithotripsies increases the likelihood of long-term adverse effects. The typical pace of 120 shock waves per minute has been shown to have much lower success rates than when the therapy is administered at a rate of 60 shock waves per minute (or slower). Furthermore, the risk of harm can be decreased by lowering the shock wave rate and implementing a short interval after the initiation of treatment. Low-to-moderate acoustic pressures and a small number of shock waves are currently the norm for treating patients in order to reduce both acute and long-term tissue damage. To help break up stones and prevent tissue damage, the shock wave rate should also be low (60 shock waves per minute or less). Answering the question of how widely these criteria are used in practice is difficult[24].

The shock wave rate serves as a real-world example of how challenging it can be to implement "best practice" recommendations. This example can also be used to show how the treatment procedure is affected by the competing needs of the clinical context. Few urologists have been able to apply this straightforward but efficient method to lower the shock wave rate, despite strong evidence to the contrary. As the shock wave rate decreases, the therapy duration lengthens. It might not be feasible to reduce the shock wave rate for a stone center that handles a dozen or more cases per day. Additionally, numerous SWL technicians and urologists are required to adhere to a predetermined protocol that is mandated by their institution or service. For many private hospitals and locations that are served by particular mobile providers, this is the situation. As a result, the urologist is released from accountability for a crucial component of the therapy [25].

It is reasonable to anticipate that academic urologists would be the least susceptible to this classification; however, an inadequate knowledge base could be a contributing factor in any environment. Another parameter that is likely to vary depending on the clinical environment is the total shock wave dose. In situations where the re-treatment opportunity is restricted due to limited access to a lithotripter, there is a normal inclination to administer the shock waves maximum number permissible in order to increase the complete comminution in a single session. In the same way, the ability to re-treat is facilitated by the lithotripsy availability, which results in an increase in the shock waves total number delivered. It is possible that the best course of action will be taken if the urologist is allowed to set up the shock wave delivery protocol and use techniques that have been proven to improve results and lessen side effects [26].

- **Practical steps to improve outcomes**

It is anticipated that the procedures deemed "best practice" in SWL will change as more study is done on the mechanics of shock wave action in tissue injury and stone fracture, as well as the biological response to shock waves is more known and described. Recent years have seen significant advances in research that have discovered a number of crucial elements that can affect the outcomes of SWL and potentially reduce the likelihood of negative consequences **(Table 2)**. In summary, they have offered new perspectives on the significance of fundamental technique, including the optimal method of adapting the shock head to the patient and the impact of treatment settings on tissue injury and stone fracture, as well as the sequence of shock wave delivery [27].

Table 2: Treatment strategies to improve outcomes and reduce adverse effects [28]

Strategy	Effect
Slow shock wave rate (<120 shock waves per min)	Improved success rates
Slow shock wave rate	Reduced renal injury
Step-wise power ramping	Low complication rate
Two-step power ramping	Reduced kidney injury
Brief pause between ramping steps	Reduced renal injury
Minimal handling of gel; proper method of applying gel	Reduced coupling defects

- **Improving acoustic coupling**

Unlike the Dornier HM3's water-tub design, modern lithotripters are dry-head devices that require the treatment head to come into contact with the patient. The only machine now in use that uses a partial water reservoir for shock head coupling is the Storz SLX. design, but contemporary lithotripters are dry-head apparatuses that need the patient to come into contact with the treatment head. The Storz SLX is the sole machine in operation today that utilizes a partial water reservoir for shock head coupling. A handful of lubricant is typically applied to the cushion of the treatment head and to the contact area on the patient's skin during coupling. The stone is targeted, the treatment head is pressed against the epidermis, and the procedure is initiated. There is typically minimal concern regarding the coupling nature. Nevertheless, the probability of air pockets becoming entrapped at the coupling interface increases as the gel is handled [(21)].

Water and coupling polymers are an excellent medium for the shock waves propagation; however, air is not an effective medium. In fact, an air compartment will reflect over 99% of SWL. Stone fracturing can be influenced by even the smallest coupling defects. In vitro tests using a test tube with a Mylar membrane as a surrogate body wall decreased the fracture of the model stones by 20–40%. This effect was noted for flaws with only 2% coverage. The acoustic energy transmission measured at the focal point was reduced by over 50% as a result of the break and re-establishment of contact. The manner in which the gel is administered and handled can enhance the quality of coupling. Apply the gel in a mound to the middle of the treatment head straight from the stock bottle while pressing the cushion up against the patient. This method works. Increasing the cushion's water inflation pressure causes the gel to spread significantly more. Despite its seeming insignificance, the coupling problem is crucial because inadequate coupling and coupling variability are likely to yield inconsistent and inferior outcomes [(29)].

- **Slowing the shock wave rate**

The fact that tissue injury and stone breakage are dose-dependent is readily apparent. It appears less logical that the shock waves rate should have a similar impact on the results. According to three prospective clinical trials and an independent meta-analysis, however, stone fracture outcomes are better with 60 shock waves per minute than with 120 shock waves per minute. Recent studies on acute renal injury in the pig model also showed that tissue damage decreased at a rate of 60 shock waves per minute, or even more slowly. According to laboratory studies, the mechanisms underlying the shock wave rate effect differ for tissue damage and stone fracture. By collapsing near the stone surface, cavitation bubbles in stone fracture primarily serve to dissolve fragments too tiny to be impacted by internal shear stresses produced by the shock front passage. The magnitude and duration of the shock wave's negative pressure phase determine cavitation, or the violent dissolution of bubbles [(22)].

Cavitation increases at a rapid shock wave rate due to the persistence of microbubbles produced during bubble collapse, which promote the new bubbles formation between pulses. The shock wave negative pressure is diminished by the expansion of these small bubbles, and the dynamics of the bubbles are altered by the increase in their number, which impacts the energy delivered to the stone. As a result, shock waves speed up the formation of bubbles, but they are less successful in attacking the stone surface. Although it does it in a very different way, cavitation also plays a role in tissue damage. In the blood, bubbles are thought to cause harm to the vessel wall when they expand or contract. Vascular injury in SWL could occur more frequently if cavitation were to occur more frequently within patent vessels. Fortunately, this is not the case [(30)].

Cavitation within tissue is a consequence of injury that is initiated by shear, according to an alternative hypothesis. Numerical modeling indicates that the shock wave rate threshold for tissue relaxation is approximately 1 Hz. If the shock wave rate is higher than the displacement relaxation time, tension may build up inside the kidney tissue. This might lead to shear and vascular rupture, which could cause blood to extravasate and pool, thereby increasing tissue damage and producing severe cavitation. Consequently, it is anticipated that rates exceeding 60 shock waves per minute would induce tissue deformation, which could result in injury. Recent research in the pig model has shown that renal injury can be significantly decrease by reducing the shock wave delivery rate **(Figure 1)** [(31)].

Pigs were subjected to 120, 60, or 30 shock waves per minute in separate experiments via a Dornier HM3 lithotripter that was operated at 24 kV. However, the lesions of the animals treated at a slower rate were considerably smaller than those of the piglets treated at a faster rate. This discovery has the potential to be of significant significance, as it implies that the lithotripter's discharge rate can be reduced to protect against SWL trauma. The implementation of a delayed shock wave rate has presented practical challenges for the majority of centers. Nevertheless, the notion that a reduced rate is both protective and hastens stone disintegration renders this a treatment strategy that is appealing (32).



Figure 1: Kidneys from three pigs treated by SWL. The top row shows surface views, and the bottom row is the corresponding tissue section. a | This kidney received the dose of shock waves recommended for clinical treatment (1,500 shock waves, 9.3 kV, 27 shock waves per min) using the Xi Xin XX-ES CS-2012A lithotripter. No surface or parenchymal bleeding was observed, and lesion size was 0% of functional renal volume (FRV). The XX-ES is currently the only lithotripter recommended for use at a firing rate of less than 60 shock waves per min. b | This kidney also received 1,500 shock waves, but with a Dornier HM3 lithotripter at 30 shock waves per min (18 kV). No surface bleeding was observed, but several small sites of hemorrhage could be seen isolated to the renal papillae (arrows). Lesion size was 0.1% FRV. c | This kidney was treated with the HM3 lithotripter at 120 shock waves per min (2,000 shock waves, 24 kV). Injury included a subcapsular hematoma (asterisk) and sites of cortical and papillary hemorrhage (arrows). Lesion size in this kidney measured 1.5% FRV. A study using the pig model has shown that treatment with the HM3 lithotripter at 60 shock waves per min is also protective compared to 120 shock waves per min (lesion size: 0.42% FRV and 3.93% FRV, respectively) (28)

- **Sequence of shock wave delivery**

The sequence in which shock waves are administered to the patient, determining the shock waves number and the cadence at a specific power level, can significantly impact tissue injury and influence stone breakage. 'Power ramping' is a technique that was involved over 20 years ago for anaesthesia-free lithotripsy. It involves progressively increasing the shock wave intensity to acclimatise the patient to the treatment. Regardless of the anesthesia regimen employed, this protocol is still adhered to in some capacity at the majority of institutions. There is no universal ratcheting (or step-wise) protocol, urologists, and technicians typically implement the approach that is most effective in their specific context. This method frequently entails the increase of the power setting on-the-fly in two or more steps, followed by the establishment of a higher level for the remainder of the treatment, which is less the maximum setting for the lithotripter. Typically, these processes entail a nominal number of shoots. Power ramping has been demonstrated to encourage stone breaking both in vitro and with model stones surgically implanted in pigs. It has also been reported to improve patient success rates. Low bleeding rates could potentially be the result of step-wise treatment (27).

Studies employing the pig model have demonstrated that a two-step power ramping technique considerably reduces kidney damage. However, the low-to-high step is unprotected. After receiving 100 shock waves at 18 kV as opposed to 2,000 shock waves at 24 kV, the lesion was significantly smaller. However, the size of the lesion was also reduced by 100 shock waves at 24 kV and then 2,000 shock waves at 24 kV. The short interval (about three minutes) between the two dosages was the main cause of the protective effect. The level of protection was remarkable. This discovery is a strong endorsement of the notion that step-wise treatment is advantageous [33].

To ensure safety, it appears sensible to suggest a pause procedure, since sequential methods have been shown to increase success rates. Thus, in the majority of clinical circumstances, a brief break in therapy should be feasible. For renal and ureteric stones, ESWL has been regarded as a basic treatment since 1984. In the UK, it is regarded by the National Institute for Health and Care Excellence (NICE) as the best course of therapy for small and medium-sized stones, and most guidelines presently suggest it. Nevertheless, a sizable portion of patients have an inadequate stone-free rate after ESWL. Urinary stones and other hard concretions are broken up into manageable pieces using external equipment that creates powerful pressure waves [34].

This method is notable for its non-invasive nature, which allows shock waves to pass through body tissues, focuses energy on the stone and reduces patient distress while enabling faster recovery. ESWL is contrasted with alternative stone treatment methods, particularly ureteroscopy, to emphasise greater patient tolerance, its minimal invasiveness, and cost-effectiveness. Furthermore, by highlighting the integrated healthcare team's joint efforts in patient assessment and care, this approach improves comprehension and competency in delivering ESWL, resulting in better outcomes for patients with nephrolithiasis. Further study of the adjuvant therapy to improve this outcome is required [35].

- **Medical expulsion therapy**

Before the use of CCBs and alpha antagonists, greater fluid intake, antiemetics, and analgesics helped promote spontaneous transit. The development of focused medical treatments was facilitated by research into the physiology of smooth muscles and the identification of adrenergic receptors in the human ureter. The advantages of CCBs and adrenergic receptor antagonists were initially shown in animal models, as is the case with most medical advances [36].

The AUA/EAU recommendations panel has conducted an additional evaluation of all available evidence regarding the use of CCBs and alpha antagonists.. According to the panel, nifedipine increased stone-passage rates by 9% in comparison to alpha antagonists, which increased rates by 29% in comparison to the control. Alpha antagonists produced statistically significant results, while nifedipine produced statistically insignificant results. Head-to-head comparisons between these two medication classes revealed that alpha antagonists were more efficacious than CCBs. The data that medical therapy with either kind of agent aids stone passing has been evaluated and validated by other authors. An investigation revealed that the addition of these medications significantly enhanced spontaneous stone ejection in comparison to standard treatment. Alpha-antagonist-treated patients had a relative risk (RR) of 1.59 and a number needed to treat of 3.3. The RR for CCBs was 1.50, and the number that needed to be treated was 3.9 [37].

The subgroup analysis of trials that employed antibiotics, low-dose steroids, and anticholinergic agents (in addition to CCBs and alpha antagonists) did not produce any additional benefits. Patients who were administered alpha antagonists experienced a 4% incidence of adverse effects, including transient hypotension, headaches, vertigo, and nausea/vomiting, while those who administered CCBs experienced a 15.2% incidence. The inclusion of corticosteroids has been shown to be advantageous by other researchers [38] .

Hermanns and colleagues [39] One hundred patients with ureteral stones less than or equal to 7 mm distal were assigned at random to receive either tamsulosin or a placebo. The median stone size in the tamsulosin group was 4.1 mm, whereas it was 3.8 mm in the placebo group. The two groups' respective stone expulsion rates of 86.7% and 88.9% were comparable. On the other hand, the tamsulosin group needed much less analgesics. This implies that even though alpha antagonists do not always promote stone passage, they may still be helpful because they are linked to a reduction in the usage of analgesics. Alpha antagonists don't all function in the same way. Based on the bulk of research and conclusions, tamsulosin is the most commonly prescribed alpha antagonist in the United States. **Pedro and colleagues [40]** examined alfuzosin's use as the recommended drug for medical expulsive treatment. 76 instances were randomly assigned to receive alfuzosin or a placebo, and the mean stone diameters of the two groups were comparable (4.08 mm vs. 3.83 mm). Between the two groups, the stone passage rates were similar: 77.1% for the placebo group and 73.5% for the alfuzosin group. Nevertheless, the alfuzosin group exhibited reduced discomfort, as indicated by their lower pain scores and shorter passage durations.

The distal ureter is abundant in alpha adrenergic receptors. The distal ureter contains a trio of receptors: α1A, α1B, and α1D. Since the α1D receptor has the highest density, it is not surprising that specific antagonists have been developed to target it. 60 patients were randomly randomized to receive vigilant weighting, a specific α1D-adrenergic receptor antagonist, or 50 mg of naftopidil in one trial. There were no negative side effects in the instances, and the naftopidil group experienced a significantly greater stone expulsion rate (90.0% vs. 26.7%) [41].

According to previous recommendations, ureteral stones in children that are less than 3 mm in size are likely to pass spontaneously, while calculi that are larger than 4 mm frequently necessitate surgical intervention. However, more recent evidence indicates that medical expulsive therapy (MET) may be effective even for larger stones. In a randomized study of 45 children aged 3–15 years with a single ureteral stone, the stone passage rate was significant increase in cases receiving ibuprofen combined with doxazosin compared with ibuprofen alone (70.8% vs. 28.5%). Additionally, the pain episodes number and the stone expulsion time were significant reduced in the combination therapy group. Stones smaller than 5 mm were expelled at a significant higher rate than those measuring 5–10 mm (100% vs. 53.3%), and children younger than 7 years demonstrated higher stone passage rates than older children (65.2% vs. 36.3%). These results imply that children can pass larger stones than previously thought and that MET trials make sense in carefully chosen clinical settings [42].

- **Predicators of medical expulsive therapy success**

In addition to stone size and location as predictors of ureteral stone passage, imaging findings and laboratory parameters have also been shown to influence expulsion rates. Regardless of where the stone is located within the ureter, recent retrospective data assessing tamsulosin-based medical expulsive therapy found that a number of computed tomography-derived variables, such as transverse stone diameter, longitudinal stone diameter, the ureter-to-stone diameter ratio, and ureteral diameter proximal to the stone, were inversely related to successful stone passage. However, in multivariate logistic regression analysis, longitudinal stone diameter which is the maximum stone length on coronal reconstruction was the only significant predictor of stone transit. Interestingly, stone ejection rates significantly decreased at a 5 mm longitudinal diameter. In the upper and lower ureters, passage rates for 4–5 mm stones were 70% and 84.3%, respectively, while those for 5–6 mm stones were 42.9% and 44.8% [43].

- **Medical expulsive therapy with other treatment modalities**

MET usage following SWL is particularly appealing given the frequent presence of residual stone fragments after treatment. Evidence from multiple randomized controlled trials supports the MET efficacy and safety in this setting. A large systematic review of randomized studies evaluating CCBs and alpha-blockers after SWL showed an overall improvement in stone expulsion, with a RR of 1.29 for alpha-blocker therapy and 1.57 for CCBs when compared with placebo. The majority of these studies used tamsulosin administered after SWL [44].

Patients receiving MET also experienced reduced analgesic requirements, fewer renal colic episodes, and lower hospitalization rates. Additional pooled analyses have shown an absolute improvement in stone clearance of approximately 16% with tamsulosin, corresponding to a number needed to treat six cases to achieve one additional successful clearance. Moreover, expulsion time was shortened by an average of 8 days, and pain scores and analgesic use were consistently lower in the MET groups. Randomized data further suggests that the tamsulosin benefit may be distinct for stones larger than 10 mm, with significant increase success rates than control, whereas similar outcomes were observed for stones measuring 4–10 mm. Overall, aggregated evidence indicates that tamsulosin-based MET following SWL results in an approximate 24% improvement in stone clearance and represents a valuable adjunct to SWL in appropriately selected patients [45].

In a study by **Hashem et al.,** [46] cases had renal stones underwent outpatient ESWL, followed by analgesics and oral tamsulosin (0.4 mg/day) for three months or until they became stone free. In a study by **Maldonado-Valadez et al.,** [35] individuals had renal stones underwent an outpatient ESWL procedure, followed by analgesics and oral tamsulosin (0.4 mg once daily) for eight weeks. Tamsulosin demonstrated an efficacy of 53.57%. In another study, individuals with renal stones underwent three sessions of ESWL. Subsequently, oral tamsulosin (0.4 mg/day) was administered for one day following each session. Tamsulosin had an efficacy rate of 94.1%.

The application of MET is not restricted to SWL **John and colleagues** [47] a single urologist prospectively evaluated cases had significant ureteral or renal calculi who went through underwent ureteroscopic laser lithotripsy. Following treatment, the cases were randomly assigned to receive either tamsulosin or a placebo. 86.5% and 69.4%, respectively, were the total stone-free frequencies ($P < 0.01$). Furthermore, the relative ureteric colic rates were 5.4% and 22.2%.

Conclusion

Tamsulosin is an effective treatment for stone clearance after ESWL. Its consistent performance across patient groups makes it a beneficial adjunct in the renal calculi management, particularly that measuring ≤10 mm.

References

1. **Amer T, Osman B, Johnstone A, Mariappan M, Gupta A, Brattis N, et al.** Medical expulsive therapy for ureteric stones: Analysing the evidence from systematic reviews and meta-analysis of powered double-blinded randomised controlled trials. Arab J Urol. 2017;15(2):83-93.
2. **Almeras C, Abid N and Meria P**. 2022 Recommendations of the AFU Lithiasis Committee: Extracorporeal shock wave lithotripsy (ESWL). Prog Urol. 2023;33(14):812-24.
3. **Huang W, Xue P, Zong H and Zhang Y**. Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(1):13-22.
4. **Kachkoul R, Touimi GB, El Mouhri G, El Habbani R, Mohim M and Lahrichi A**. Urolithiasis: History, epidemiology, aetiologic factors and management. Malays J Pathol. 2023;45(3):333-52.
5. **Qian X, Wan J, Xu J, Liu C, Zhong M, Zhang J, et al.** Epidemiological Trends of Urolithiasis at the Global, Regional, and National Levels: A Population-Based Study. Int J Clin Pract. 2022;2022:68-77.
6. **Khan SR, Canales BK and Dominguez-Gutierrez PR**. Randall's plaque and calcium oxalate stone formation: role for immunity and inflammation. Nat Rev Nephrol. 2021;17(6):417-33.
7. **Wang Z, Zhang Y, Zhang J, Deng Q and Liang H**. Recent advances on the mechanisms of kidney stone formation (Review). Int J Mol Med. 2021;48(2):45-63.
8. **Elhammady MS, Ambekar S and Heros RC**. Epidemiology, clinical presentation, diagnostic evaluation, and prognosis of cerebral dural arteriovenous fistulas. Handb Clin Neurol. 2017;143:99-105.
9. **Simmons KE, Nair HR, Phadke M, Motamedinia P, Singh D, Montgomery TA, et al.** Risk Factors for Common Kidney Stones Are Correlated with Kidney Function Independent of Stone Composition. Am J Nephrol. 2023;54(7):329-36.
10. **Asplin JR**. Bowel Disease and Urolithiasis. Kidney Stones: Medical and Surgical Management2019. p. 37-64.
11. **John TT and Razdan S**. Adjunctive tamsulosin improves stone free rate after ureteroscopic lithotripsy of large renal and ureteric calculi: a prospective randomized study. Urology. 2010;75(5):1040-2.

12. **Shastri S, Patel J, Sambandam KK and Lederer ED**. Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023. Am J Kidney Dis. 2023;82(5):617-34.

13. **Rokni E, Zinck S and Simon JC**. Evaluation of Stone Features That Cause the Color Doppler Ultrasound Twinkling Artifact. Ultrasound Med Biol. 2021;47(5):1310-8.

14. **Sromicki J and Hess B**. Simple dietary advice targeting five urinary parameters reduces urinary supersaturation in idiopathic calcium oxalate stone formers. Urolithiasis. 2020;48(5):425-33.

15. **De Coninck V, Skolarikos A, Juliebø-Jones P, Joris M, Traxer O and Keller EX**. Advancements in stone classification: unveiling the beauty of urolithiasis. World J Urol. 2024;42(1):46-56.

16. **Adomako E and Moe OW**. Uric acid and urate in urolithiasis: the innocent bystander, instigator, and perpetrator. Semin nephrol. 2020;40(6):564-73.

17. **Peerapen P and Thongboonkerd V**. Kidney Stone Prevention. Adv Nutr. 2023;14(3):555-69.

18. **Sadiq S and Cil O**. Cystinuria: An Overview of Diagnosis and Medical Management. Turk Arch Pediatr. 2022;57(4):377-84.

19. **Katz JE, Clavijo RI, Rizk P and Ramasamy R**. The Basic Physics of Waves, Soundwaves, and Shockwaves for Erectile Dysfunction. Sex Med Rev. 2020;8(1):100-5.

20. **Dresner SL, Iremashvili V, Best SL, Hedican SP and Nakada SY**. Influence of Lower Pole Infundibulopelvic Angle on Success of Retrograde Flexible Ureteroscopy and Laser Lithotripsy for the Treatment of Renal Stones. J Endourol. 2020;34(6):655-60.

21. **Elmansy HE and Lingeman JE**. Recent advances in lithotripsy technology and treatment strategies: A systematic review update. Int J Surg. 2016;36:676-80.

22. **Yoon JH, Park S, Kim SC, Park S, Moon KH, Cheon SH, et al.** Outcomes of extracorporeal shock wave lithotripsy for ureteral stones according to ESWL intensity. Transl Androl Urol. 2021;10(4):1588-95.

23. **Kayra MV, GOREN MR, Ozer C and Kilinc F**. The factors that affecting shockwave lithotripsy treatment outcome of kidney stones. Authorea Preprints. 2021:33-45.

24. **Ito K, Takahashi T, Kanno T, Okada T, Higashi Y and Yamada H**. Extremely-slow, half-number shockwave lithotripsy for asymptomatic renal stones <20 mm. Investig Clin Urol. 2021;62(1):72-8.

25. **Rola P, Włodarczak A, Barycki M and Doroszko A**. Use of the Shock Wave Therapy in Basic Research and Clinical Applications—From Bench to Bedsite. Biomedicines. 2022;10(3):56-68.

26. **Zeng G, Zhong W, Chaussy CG, Tiselius HG, Xu C, Turney B, et al.** International Alliance of Urolithiasis Guideline on Shockwave Lithotripsy. Eur Urol Focus. 2023;9(3):513-23.

27. **Lee SM, Collin N, Wiseman H and Philip J**. Optimisation of shock wave lithotripsy: a systematic review of technical aspects to improve outcomes. Transl Androl Urol. 2019;8(4):89-97.

28. **Lingeman JE, McAteer JA, Gnessin E and Evan AP**. Shock wave lithotripsy: advances in technology and technique. Nat Rev Urol. 2009;6(12):660-70.

29. **Connors BA, Schaefer RB, Gallagher JJ, Johnson CD, Li G, Handa RK, et al.** Preliminary Report on Stone Breakage and Lesion Size Produced by a New Extracorporeal Electrohydraulic (Sparker Array) Discharge Device. Urology. 2018;116:213-7.

30. **Tinguely M, Ohtani K, Farhat M and Sato T**. Observation of the Formation of Multiple Shock Waves at the Collapse of Cavitation Bubbles for Improvement of Energy Convergence. Energies. 2022;15(7):23-45.

31. **Hunter C, Cunitz B, Dunmire B, Bailey M, Randad A, Kreider W, et al.** Impact of stone characteristics on cavitation in burst wave lithotripsy. Proc Meet Acoust. 2018;35(1):36-74.

32. **Connors BA, Gardner T, Liu Z, Lingeman JE and Williams JC, Jr.** Renal Protection Phenomenon Observed in a Porcine Model After Electromagnetic Lithotripsy Using a Treatment Pause. J Endourol. 2021;35(5):682-6.

33. **Connors BA, Evan AP, Handa RK, Blomgren PM, Johnson CD, Liu Z, et al.** Using 300 Pretreatment Shock Waves in a Voltage Ramping Protocol Can Significantly Reduce Tissue Injury During Extracorporeal Shock Wave Lithotripsy. J Endourol. 2016;30(9):1004-8.

34. **Hughes T, Ho HC, Pietropaolo A and Somani BK**. Guideline of guidelines for kidney and bladder stones. Turk J Urol. 2020;46(1):104-12.

35. **Maldonado-Valadez RE, Valdez-Vargas AD, Alvarez JA and Rodea-Montero ER**. Efficacy of Adjuvant Tamsulosin for Improving the Stone-Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones: A Randomized Controlled Trial. Int J Clin Pract. 2022;2022:37-57.

36. **De Coninck V, Antonelli J, Chew B, Patterson JM, Skolarikos A and Bultitude M**. Medical Expulsive Therapy for Urinary Stones: Future Trends and Knowledge Gaps. Eur Urol. 2019;76(5):658-66.

37. **Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck C, Gallucci M, et al.** 2007 guideline for the management of ureteral calculi. J Urol. 2007;178(6):18-34.

38. **Skylynn T, Abel T, Christopher L, Suliman G, Dominic R, Joel V, et al.** Benefits and Risks of Medications Used in the Management of Hypotension: A Review. Cureus. 2024;16(1):45-78.

39. **Hermanns T, Sauermann P, Rufibach K, Frauenfelder T, Sulser T and Strebel RT**. Is there a role for tamsulosin in the treatment of distal ureteral stones of 7 mm or less? Results of a randomised, double-blind, placebo-controlled trial. Eur Urol. 2009;56(3):407-12.

40. **Pedro RN, Hinck B, Hendlin K, Feia K, Canales BK and Monga M**. Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study. J Urol. 2008;179(6):22-45.

41. **Lim I, Sellers DJ and Chess-Williams R**. Current and emerging pharmacological targets for medical expulsive therapy. Basic Clin Pharmacol Toxicol. 2022;1:16-22.

42. **Ziaeefar P, Basiri A, Zangiabadian M, de la Rosette J, Zargar H, Taheri M, et al.** Medical Expulsive Therapy for Pediatric Ureteral Stones: A Meta-Analysis of Randomized Clinical Trials. J Clin Med. 2023;12(4):36-45.

43. **Shivanna N, Singh AK and Laddha PJ**. The Efficacy of Tamsulosin as Medical Expulsion Therapy in Ureteric Calculus of <8 mm Size. J Datta Meghe Inst Med Sci Univ. 2018;13(4):33-65.

44. **Skolarikos A, Grivas N, Kallidonis P, Mourmouris P, Rountos T, Fiamegos A, et al.** The Efficacy of Medical Expulsive Therapy (MET) in Improving Stone-free Rate and Stone Expulsion Time, After Extracorporeal Shock Wave Lithotripsy (SWL) for Upper Urinary Stones: A Systematic Review and Meta-analysis. Urology. 2015;86(6):1057-64.

45. **Motov S, Drapkin J, Butt M, Thorson A, Likourezos A, Flom P, et al.** Analgesic Administration for Patients with Renal Colic in the Emergency Department Before and After Implementation of an Opioid Reduction Initiative. West J Emerg Med. 2018;19(6):1028-35.

46. **Hashem A, El-Assmy AM, Sharaf DE, Elgamal M, Elzalouey AE and Laymon M**. A randomized trial of adjuvant tamsulosin as a medical expulsive therapy for renal stones after shock wave lithotripsy. Urolithiasis. 2022;50(4):473-80.